Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? (original) (raw)

“…It is known that in patients receiving bevacizumab, a monoclonal anti-VEGF antibody, therapy resistance or disease progression can be expected due to the upregulation of placental growth factor, plateletderived growth factor, and FGF [25].…”

Section: Discussionmentioning

“…It is known that in patients receiving bevacizumab, a monoclonal anti-VEGF antibody, therapy resistance or disease progression can be expected due to the upregulation of placental growth factor, plateletderived growth factor, and FGF [25].…”

Section: Discussionmentioning

“…Although the molecular mechanisms involved in the activation of angiogenesis are well understood, many antiangiogenic therapies have failed due to alternative molecular escape routes [ 68 ]. In this context, another important point to be considered is the cellular component of the angiogenesis process.…”

Section: Epcs In Cancer Angiogenesismentioning

“…Výzkum započal již v roce 1997 [1] a v současnosti je k dispozici ně-kolik molekul a další jsou předmětem klinických zkoušek [2]. Za cíl mají blokádu novotvorby nádorových cév a potažmo i metastazování, které má související mechanizmus, a možnosti terapeutické intervence se stále rozvíjejí [3,4].…”

Section: Východiskaunclassified